Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study

NCT04001634 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04001634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04001634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
Lead sponsor
Fudan University
Phase
Observational
Overall status
Completed
Start date
January 1, 2015
Completion date
August 15, 2020
Enrollment
285 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer